🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I greatly appreciate the mentorship of Drs. Lawrence Fong Lawrence Fong MD and Lauren Ehrlich and support from PICI Parker Institute for Cancer Immunotherapy UCSF School of Medicine. Huge congrats to the other awardees.

We are happy to share our work led by Aram Lyu and Zenghua Fan on why prostate cancer is so resistant to immunotherapy. nature.com/articles/s4158…

Nature research paper: Evolution of myeloid-mediated immunotherapy resistance in prostate cancer go.nature.com/4f2rSNq

Why has immunotherapy, transformative for some cancers, struggled in prostate cancer? A new nature study, led by Lawrence Fong MD (former PICI Co-Director at UC San Francisco, now at Fred Hutch Cancer Center) with 1st author Aram Lyu, PhD (PICI Investigator, UCSF), uncovers key insights. 1/3

Fred Hutch researchers shared new research at the Society for Immunotherapy of Cancer meeting in early Nov. Findings included new strategies to avoid T-cell exhaustion in CAR T cells & insights into how solid tumors change microenvironment to blunt the immune system’s response. bit.ly/4gbmvwI

ScRNAseq of prostate cancer samples revealed an SPP1hi TAM population that correlated with progression and T cell exhaustion. bit.ly/3ZPj4Fk  Aram Lyu  Parker Institute for Cancer Immunotherapy  Lawrence Fong MD

How do prostate tumor cells dodge the immune system? jci.org/articles/view/… Ru Wen & team reveal an interaction between sialic acid-modified proteins on tumor cells and Siglec7/9 on immune cells and identify CD59 as a candidate for targeting! Jessica Stark Nick Riley

Aram Lyu, Peiqi Ou, Helen Rizos, and Annette Paschen discuss "Cancer Immune Evasion" in a symposium at the AACR IO Conference on Discovery and Innovation in Cancer Immunology. #AACRIO25 Helen Rizos Aram Lyu

In this fantastic collaboration with Abbvie we were able to find time-sensitive synergistic effects between immune checkpoint blockade and JAK1 inhibition in boosting T cell fitness against tumors in mice. Online today! insight.jci.org/articles/view/… Lawrence Fong MD

Think global, act local! Just like the fully cleavable, conditionally activatable DVD CTLA4 blockade we report at jitc.bmj.com/content/13/4/e… ! It provided safe, primary antigen-specific antitumor efficacy in localized and systemic preclinical tumor models. Lawrence Fong MD

ASCI member Fong et al. UC San Francisco show that JAK inhibition administered sequentially enhances anti-tumor immunity after combined anti-PD-1 and anti-CTLA4 therapy in pre-clinical prostate cancer study: insight.jci.org/articles/view/…

The 2024 Young Investigator Awards recipients have just been announced. Congrats to this year’s class, who received $6.3 million in funding for innovative prostate cancer research. Meet this year’s class: bit.ly/YIAwardsClass2… #ProstateCancer #MedEd #MedX